SA's health regulator warns against buying weight-loss, diabetes meds from unregulated sources
SAHPRA said that these products, often sold online or through informal channels, could be counterfeit or of substandard quality, and their safety and effectiveness have not been verified.
Photo: Unsplash/Sweet Life (cropped)
JOHANNESBURG - The South African Health Products Regulatory Authority (SAHPRA) has warned the public about the risks of purchasing unregistered and potentially dangerous weight-loss and diabetes medication, including Ozempic and Mounjaro, from unofficial or unregulated sources.
SAHPRA said that these products, often sold online or through informal channels, could be counterfeit or of substandard quality, and their safety and effectiveness have not been verified.
The regulatory body raised concern about the sale of compounded versions of these medications, which contain active ingredients used to treat Type 2 diabetes and assist with weight loss.
These compounded drugs are not assessed by SAHPRA, meaning they may pose serious health risks.
SAHPRA CEO Dr Boitumelo Semete-Makokotlela emphasised that the authority is closely monitoring the sale of unregistered medications and is investigating any violations.
Spokesperson Madimetja Mashishi explained: "The public is urged to report any suspected products that are falsely claiming to be available or sold like Ozempic and Mounjaro. You can report through these whistleblower platforms, SAHPRA’s 24-hour hotline (0800 204 307) or via our web reporting facility.”
She urged consumers to buy medications officially registered and approved by SAPHRA to ensure their safety.
SAHPRA also warned that selling unregistered or falsified medicine is illegal and carries serious penalties.